New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - piroxicam betadex 191.2mg equivalent to 20 mg piroxicam - tablet - 20 mg - active: piroxicam betadex 191.2mg equivalent to 20 mg piroxicam excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate pregelatinised maize starch sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - piroxicam betadex 191.2mg equivalent to 20 mg piroxicam - oral granules - 20 mg - active: piroxicam betadex 191.2mg equivalent to 20 mg piroxicam excipient: aspartame colloidal silicon dioxide sorbitol

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 10 mg - carefully consider the potential benefits and risks of piroxicam capsules, usp and other treatment options before deciding to use piroxicam capsules, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). piroxicam capsules, usp is indicated: - for relief of the signs and symptoms of osteoarthritis. - for relief of the signs and symptoms of rheumatoid arthritis. piroxicam capsules, usp is contraindicated in patients with known hypersensitivity to piroxicam. piroxicam capsules, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reactions and precautions: preexisting asthma ). piroxicam capsules, usp is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see w

United States - English - NLM (National Library of Medicine)

a-s medication solutions - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 20 mg - carefully consider the potential benefits and risks of piroxicam capsules, usp and other treatment options before deciding to use piroxicam capsules, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). piroxicam capsules, usp is indicated: piroxicam capsules, usp is contraindicated in patients with known hypersensitivity to piroxicam. piroxicam capsules, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reactions and precautions: preexisting asthma ). piroxicam capsules, usp is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 10 mg - piroxicam capsules are indicated: piroxicam is contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting at 30 weeks gestation. risk summary use of nsaids, including piroxicam, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including piroxicam, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of piroxicam in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2 to 4% for major malformations, and 15 to 20% for pregnancy loss. in animal reproduction studies in rats and rabbits, there was no evidence of teratogenicity at exposures up to 5 and 10 times the mrhd,

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 10 mg - carefully consider the potential benefits and risks of piroxicam capsules and other treatment options before deciding to use piroxicam capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). piroxicam capsules are indicated: piroxicam capsules are contraindicated in patients with known hypersensitivity to piroxicam. piroxicam capsules should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reactions and precautions: preexisting asthma ). piroxicam capsules are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

Canada - English - Health Canada

chiesi farmaceutici s.p.a. - piroxicam b-cyclodextrin - tablet - 191.2mg - piroxicam b-cyclodextrin 191.2mg - other nonsteroidal antiimflammatory agents

United States - English - NLM (National Library of Medicine)

nivagen pharmaceuticals, inc - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 10 mg - piroxicam capsules usp is indicated: -   for relief of the signs and symptoms of osteoarthritis. -   for relief of the signs and symptoms of rheumatoid arthritis. piroxicam capsules usp is contraindicated in the following patients: -   known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to piroxicam or any components of the drug product [see warnings and precautions (5.7 , 5.9)] -   history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7 , 5.8)] -   in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] pregnancy category c prior to 30 weeks gestation; category d starting at 30 weeks gestation. risk summary use of nsaids, including piroxicam capsules usp, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosu

United States - English - NLM (National Library of Medicine)

unit dose services - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 20 mg - carefully consider the potential benefits and risks of piroxicam capsules, usp and other treatment options before deciding to use piroxicam capsules, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). piroxicam capsules, usp is indicated: - for relief of the signs and symptoms of osteoarthritis. - for relief of the signs and symptoms of rheumatoid arthritis. piroxicam capsules, usp is contraindicated in patients with known hypersensitivity to piroxicam. piroxicam capsules, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactoid reactions and precautions: preexisting asthma ). piroxicam capsules, usp is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see w

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - piroxicam (unii: 13t4o6vmam) (piroxicam - unii:13t4o6vmam) - piroxicam 20 mg - piroxicam capsules are indicated: - for relief of the signs and symptoms of osteoarthritis. - for relief of the signs and symptoms of rheumatoid arthritis. piroxicam is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to piroxicam or any components of the drug product [see warnings and precautions ( 5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions ( 5.7, 5.8)] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions ( 5.1)] pregnancy category c prior to 30 weeks gestation; category d starting at 30 weeks gestation. risk summary use of nsaids, including piroxicam, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including piroxica